Autonomix Medical announced today that it completed an animal safety study evaluating its proprietary ablation technology.
The Woodlands, Texas-based company designed its tissue ablation technology to address pancreatic cancer-related pain. Current approaches, like opioids or ethanol injections, may only provide limited relief and may lead to risky side effects. The company hopes its proof-of-concept effort opens the door to a “novel, blockbuster disease treatment.”
In the Autonomix evaluation utilizing a porcine, multi-arterial model, the study met all safety inputs. The company reported no procedure-related side effects.
Autonomix designed its study to assess the acute saefty and feasibility of its tissue ablation. Key points included the ability to reach the distal artery region’s ablation targets using the catheter, performing ablation steps effectively and monitoring for potential adverse effects in a three-day observation period post-ablation.
Findings showed successful energy delivery and no acute complications using several of Autonomix’s proprietary ablation catheters.
Based on the outcomes, Autonomix now plans to move toward a first-in-human clinical study of its radiofrequency ablation. It expects to commence enrollment in the first quarter of 2024.
“We are very pleased with the outcome of this important safety study, and we continue to execute on developing our potentially groundbreaking technology. The successful completion of this preclinical safety study provides us with supportive data as we advance toward our first-in-human clinical study, a catalytic milestone for Autonomix,” said Lori Bisson, CEO of Autonomix.